Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vidaza, Mylosar
5-Azacytidine, also known as azacitidine, is an antineoplastic antimetabolite analog of cytidine. It is used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It works by incorporating into DNA and RNA, inhibiting DNA methyltransferase, and leading to hypomethylation of DNA. This can restore normal gene function and induce differentiation or apoptosis of malignant cells.
For the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Severe myelosuppression, including profound neutropenia, thrombocytopenia, and anemia, can occur. Patients must be monitored closely for hematologic toxicity. Hepatic toxicity, including hepatic failure, can occur.
Outcome:
Increased risk of myelosuppression
Mechanism:
Additive myelosuppressive effects
Outcome:
Increased risk of hypotension
Mechanism:
Additive hypotensive effects
Outcome:
Reduced azacitidine absorption
Mechanism:
Changes in stomach pH
Most likely new formulation: Oral sustained-release formulation (Year 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of expanded indications for 5-azacytidine within the next 5 years.
Antineoplastic, Antimetabolite, Pyrimidine analog
Pyrimidine nucleoside analog